Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.67 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12229701 | 0.90 | MAPK14 (0.70) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL12229806 | 0.90 | MAPK14 (0.70) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL12252384 | 0.89 | MAPK14 (0.68) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL2537333 | 0.89 | MAPK14 (0.84) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL14437817 | 0.89 | MAPK14 (0.68) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL2543274 | 0.87 | MAPK14 (0.66) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL12254571 | 0.87 | MAPK14 (0.71) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL12229695 | 0.86 | MAPK14 (0.50) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL12229688 | 0.86 | MAPK14 (0.50) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL2539233 | 0.86 | MAPK14 (0.68) | MAPK14MAPK11MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044040-B2 | e.g. 3-{3-Cyano-6-[(2,2-dimethyl-propyl)-methyl-amino]-5-fluoro-pyridin-2-ylamino}-N-methoxy-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20080015185-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-7253174-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015185-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | TNF, RELA, NFKBIA | MAPK14 113/4885MAPK11 140/4885MAPK13 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.